sur Heidelberg Pharma AG (ETR:HPHA)
Heidelberg Pharma Appoints Dr. Liu as CEO Amid Management Changes
Heidelberg Pharma AG, a German biotech firm focusing on Antibody Drug Conjugates (ADCs), has announced a significant shift in its executive management. The Supervisory Board has removed Professor Andreas Pahl from his role as CEO, appointing Dr. Dongzhou Jeffery Liu as both Chairman of the Executive Board and CEO, effective immediately.
Dr. Liu transitions from the Supervisory Board to his new role, officially starting December 24, 2025. His background includes leadership positions at Huadong Medicine and major pharmaceutical companies in the US, with over 25 years in clinical and preclinical research.
Dr. Karl Benedikt Biesinger, Chairman of the Supervisory Board, expressed gratitude for Professor Pahl’s contributions, highlighting his influence on the lead clinical project HDP-101. Dr. Liu is optimistic about advancing Heidelberg Pharma’s ATAC technology in cancer treatment.
R. E.
Copyright © 2025 FinanzWire, tous droits de reproduction et de représentation réservés.
Clause de non responsabilité : bien que puisées aux meilleures sources, les informations et analyses diffusées par FinanzWire sont fournies à titre indicatif et ne constituent en aucune manière une incitation à prendre position sur les marchés financiers.
Cliquez ici pour consulter le communiqué de presse ayant servi de base à la rédaction de cette brève
Voir toutes les actualités de Heidelberg Pharma AG